Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2021 2
2022 3
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma.
García-Sancha N, Corchado-Cobos R, Bellido-Hernández L, Román-Curto C, Cardeñoso-Álvarez E, Pérez-Losada J, Orfao A, Cañueto J. García-Sancha N, et al. Among authors: bellido hernandez l. Cancers (Basel). 2021 Oct 13;13(20):5134. doi: 10.3390/cancers13205134. Cancers (Basel). 2021. PMID: 34680282 Free PMC article. Review.
Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data.
Toribio-García I, Olivares-Hernández A, Miramontes-González JP, Domínguez LP, Martín García A, Eiros Bachiller R, Figuero-Pérez L, Garijo Martínez M, Roldán Ruiz J, Bellido Hernández L, Fonseca-Sánchez E, Luis Sánchez P, Del Barco-Morillo E. Toribio-García I, et al. Among authors: bellido hernandez l. Cancers (Basel). 2023 Aug 28;15(17):4293. doi: 10.3390/cancers15174293. Cancers (Basel). 2023. PMID: 37686569 Free PMC article.
Efficacy and safety of PARP inhibitor in non-small cell lung cancer: a systematic review with meta-analysis.
Olivares-Hernández A, Roldán-Ruiz J, Miramontes-González JP, Toribio-García I, García-Hernández JL, Posado-Domínguez L, Bellido-Hernández L, Cruz-Hernández JJ, Fonseca-Sánchez E, Del Barco-Morillo E. Olivares-Hernández A, et al. Among authors: bellido hernandez l. Chin Clin Oncol. 2023 Dec;12(6):62. doi: 10.21037/cco-23-58. Chin Clin Oncol. 2023. PMID: 38195073 Free article.
Immunohistochemical Assessment of the P53 Protein as a Predictor of Non-Small Cell Lung Cancer Response to Immunotherapy.
Olivares-Hernández A, Del Barco Morillo E, Miramontes-González JP, Figuero-Pérez L, Pérez-Belmonte L, Martín-Vallejo J, Martín-Gómez T, Escala-Cornejo R, Vidal-Tocino R, Hernández LB, Sarmiento RG, Ludeña de la Cruz MD, Cruz-Hernández JJ, Pérez CP. Olivares-Hernández A, et al. Among authors: hernandez lb. Front Biosci (Landmark Ed). 2022 Mar 8;27(3):88. doi: 10.31083/j.fbl2703088. Front Biosci (Landmark Ed). 2022. PMID: 35345320 Free article.
Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis.
Olivares-Hernández A, Del Barco Morillo E, Parra Pérez C, Miramontes-González JP, Figuero-Pérez L, Martín-Gómez T, Escala-Cornejo R, Bellido Hernández L, González Sarmiento R, Cruz-Hernández JJ, Ludeña de la Cruz MD. Olivares-Hernández A, et al. Among authors: bellido hernandez l. Biomedicines. 2022 Feb 2;10(2):360. doi: 10.3390/biomedicines10020360. Biomedicines. 2022. PMID: 35203569 Free PMC article.
Fulminant myocarditis in a patient with a lung adenocarcinoma after the third dose of modern COVID-19 vaccine. A case report and literature review.
Terán Brage E, Roldán Ruíz J, González Martín J, Oviedo Rodríguez JD, Vidal Tocino R, Rodríguez Diego S, Sánchez Hernández PL, Bellido Hernández L, Fonseca Sánchez E. Terán Brage E, et al. Among authors: bellido hernandez l. Curr Probl Cancer Case Rep. 2022 Jun;6:100153. doi: 10.1016/j.cpccr.2022.100153. Epub 2022 Mar 31. Curr Probl Cancer Case Rep. 2022. PMID: 35378738 Free PMC article.
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.
Gómez Rueda A, Taus Á, Álvarez Álvarez R, Bernabé-Caro R, Chara L, López-Brea M, Vilà L, Sala González MÁ, Del Barrio Díaz Aldagalán A, Esteban Herrera B, López Castro R, Álvarez Cabellos R, Doménech M, Falagan S, Moreno Vega A, Aguado C, Barba A, Delgado Ureña MT, Isla D, Bellido Hernández L, Fírvida Pérez JL, Juan-Vidal Ó, Massutí B, Mielgo-Rubio X, Ortega AL, Catot S, Dómine M, Escoín-Pérez C, García Navalón F, Gil-Bazo I, Muñoz S, Rodríguez-Abreu D, Villatoro Roldán RM, Alonso-Jáudenes Curbera G, León-Mateos L, Padilla A, Paredes Lario A, Sánchez-Torres JM, Garrido P; Spanish Lung Cancer Group. Gómez Rueda A, et al. Among authors: bellido hernandez l. Clin Transl Oncol. 2024 Mar 21. doi: 10.1007/s12094-024-03404-9. Online ahead of print. Clin Transl Oncol. 2024. PMID: 38512450
Response to Treatment with an Anti-Interleukin-6 Receptor Antibody (Tocilizumab) in a Patient with Hemophagocytic Syndrome Secondary to Immune Checkpoint Inhibitors.
Olivares-Hernández A, Figuero-Pérez L, Amores Martín MA, Bellido Hernández L, Mezquita L, Vidal Tocino MDR, López Cadenas F, Gómez-Caminero López F, Escala-Cornejo RA, Cruz Hernández JJ. Olivares-Hernández A, et al. Among authors: bellido hernandez l. Case Rep Oncol Med. 2021 Feb 12;2021:6631859. doi: 10.1155/2021/6631859. eCollection 2021. Case Rep Oncol Med. 2021. PMID: 33628551 Free PMC article.
Frequency and characteristics of familial melanoma in Spain: the FAM-GEM-1 Study.
Márquez-Rodas I, Martín González M, Nagore E, Gómez-Fernández C, Avilés-Izquierdo JA, Maldonado-Seral C, Soriano V, Majem-Tarruella M, Palomar V, Maseda R, Martín-Carnicero A, Puertolas T, Godoy E, Cerezuela P, Ochoa de Olza M, Campos B, Perez-Ruiz E, Soria A, Gil-Arnaiz I, Gonzalez-Cao M, Galvez E, Arance A, Belon J, de la Cruz-Merino L, Martín-Algarra S; Spanish Multidisciplinary Group of Melanoma (GEM). Márquez-Rodas I, et al. PLoS One. 2015 Apr 13;10(4):e0124239. doi: 10.1371/journal.pone.0124239. eCollection 2015. PLoS One. 2015. PMID: 25874698 Free PMC article.